Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session
Video Transcript: Robert Proulx, Imagion Biosystems’ President & CEO: [00:00:00] On April 24th, we sent out the notice of meeting for our annual general meeting
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, announces it has initiated plans to separate the
https://youtu.be/8MSNhYapsRI Highlights: Reported positive results of independent review of utility for MagSense® HER2 breast cancer detection Announced plan to advance MagSense® HER2 program to multi-site
In accordance with Listing Rule 3.17, Imagion Biosystems Limited attaches a copy of the following documents: 1. Letter to Shareholders regarding arrangements for the Annual
Imagion Biosystems (ASX:IBX) is a biotech company dedicated to improving healthcare through the earlier detection of cancer and other diseases. We are using our proprietary
We’re on a mission to make cancer more detectable.